Abstract
Tumours of the stroma (Leydig cells) and/or sex cords (Sertoli cells) represent approximately 8% of ovarian tumours and develop from the conjunctive tissue (respectively, interstitial and nurse cells) of the ovaries. Because these cells participate in ovarian hormonal function, most of the sex-cord or stromal tumours are able to secrete hormones (oestrogens, androgens, corticoids), which explains the hormonal dysfunctions associated with these cancers. Their prognoses are difficult to establish; some of the tumours are almost always benign (Sertoli cell tumours, Leydig cell tumours), whereas others are malignant but with variably delayed local-regional, or metastatic relapses. The histological criteria of aggressiveness are so poorly known that it is difficult to even propose a dichotomous, benign-malignant histopathological classification. If they do not present clinical criteria of 'malignancy', these tumours are considered to be of uncertain prognosis. In this group of tumours, the following might have 'malignant' behaviour: Granulosa cell tumours, androblastomas (or Sertoli-Leydig cell tumours), tumours of the sex cords with annealed tubules, tumours of the steroid-producing (theca) cells without any other specification, and fibrosarcomas. Surgery is the most important therapeutic modality and must be as conservative as possible to preserve reproductive function; it can be effectively combined with chemotherapy for advanced stages.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.